Detrol: Regain Control Over Overactive Bladder Symptoms
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.17 (0%) | 🛒 Add to cart |
| 60 | $1.15 | $82.33 $69.28 (16%) | 🛒 Add to cart |
| 90 | $1.08 | $123.50 $97.39 (21%) | 🛒 Add to cart |
| 120 | $1.05 | $164.66 $126.51 (23%) | 🛒 Add to cart |
| 180 | $1.02 | $247.00 $182.74 (26%) | 🛒 Add to cart |
| 270 | $0.99 | $370.50 $268.08 (28%) | 🛒 Add to cart |
| 360 | $0.98
Best per pill | $493.99 $354.43 (28%) | 🛒 Add to cart |
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.21 | $66.27 (0%) | 🛒 Add to cart |
| 60 | $1.86 | $132.54 $111.45 (16%) | 🛒 Add to cart |
| 90 | $1.75 | $198.80 $157.64 (21%) | 🛒 Add to cart |
| 120 | $1.69 | $265.07 $202.82 (23%) | 🛒 Add to cart |
| 180 | $1.63 | $397.61 $293.18 (26%) | 🛒 Add to cart |
| 270 | $1.59 | $596.41 $428.73 (28%) | 🛒 Add to cart |
| 360 | $1.57
Best per pill | $795.21 $564.28 (29%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.68 | $110.45 (0%) | 🛒 Add to cart |
| 60 | $2.86 | $220.89 $171.69 (22%) | 🛒 Add to cart |
| 90 | $2.58 | $331.34 $231.94 (30%) | 🛒 Add to cart |
| 120 | $2.43 | $441.78 $292.18 (34%) | 🛒 Add to cart |
| 180 | $2.29 | $662.68 $412.67 (38%) | 🛒 Add to cart |
| 270 | $2.21
Best per pill | $994.01 $595.40 (40%) | 🛒 Add to cart |
Synonyms | |||
Detrol (tolterodine tartrate) is a prescription medication specifically formulated for the treatment of overactive bladder (OAB). It belongs to a class of drugs known as antimuscarinics or anticholinergics, which work by relaxing the bladder muscle. This action helps to increase bladder capacity, reduce the frequency of involuntary contractions, and decrease the urgency to urinate. By targeting the underlying cause of OAB symptoms, Detrol provides a clinically proven solution for patients seeking to improve their quality of life and daily functioning.
Features
- Active ingredient: Tolterodine tartrate
- Available in immediate-release tablets (1 mg and 2 mg) and extended-release capsules (2 mg and 4 mg)
- Selective muscarinic receptor antagonist with high affinity for bladder tissue
- Demonstrated efficacy in reducing urinary frequency, urgency, and urge incontinence episodes
- Well-established pharmacokinetic profile with predictable absorption and metabolism
- Manufactured under strict quality control standards ensuring consistency and purity
Benefits
- Significantly reduces the number of urge incontinence episodes per day, allowing for greater confidence and less worry about accidents.
- Decreases urinary frequency, enabling longer intervals between bathroom visits and reducing sleep disruptions due to nocturia.
- Alleviates the sudden, strong need to urinate immediately, providing patients with more control and planning ability in daily activities.
- Improves overall quality of life by reducing the anxiety and social limitations associated with overactive bladder symptoms.
- Supports bladder retraining and behavioral therapies by providing pharmacological control of involuntary detrusor contractions.
- Offers flexible dosing options (immediate and extended release) to accommodate individual patient needs and lifestyles.
Common use
Detrol is primarily indicated for the management of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is prescribed for adults who experience these disruptive symptoms, which often interfere with work, social engagements, and sleep patterns. The medication is commonly used by both men and women, though epidemiological studies show a higher prevalence of OAB among women, particularly post-menopausal women. Detrol may be prescribed as monotherapy or as part of a comprehensive treatment plan that includes bladder training exercises, dietary modifications, and lifestyle adjustments. Clinical studies have demonstrated its effectiveness across various age groups, though dosage adjustments may be necessary for elderly patients.
Dosage and direction
The recommended initial dose for Detrol immediate-release tablets is 2 mg twice daily. Based on patient response and tolerability, the dose may be lowered to 1 mg twice daily, particularly for patients who experience side effects or those with impaired liver function. For Detrol LA extended-release capsules, the recommended dose is 4 mg once daily. This may be reduced to 2 mg once daily if the higher dose is not well tolerated. Both formulations should be taken with water and may be administered with or without food, though consistent administration with food may help minimize potential gastrointestinal discomfort. Patients should not chew, divide, or crush the extended-release capsules. Dosage adjustments are recommended for patients with significantly impaired liver function or those taking certain CYP3A4 inhibitors concurrently.
Precautions
Patients should inform their healthcare provider of any pre-existing medical conditions, particularly liver or kidney disease, bladder obstruction, gastrointestinal disorders (including ulcerative colitis), myasthenia gravis, or narrow-angle glaucoma. Regular monitoring of residual urine volume may be recommended for patients with bladder outlet obstruction. Detrol may cause blurred vision or drowsiness; patients should exercise caution when driving, operating machinery, or performing activities requiring alertness until they know how the medication affects them. Adequate hydration should be maintained unless otherwise directed by a physician, but excessive fluid intake close to bedtime may exacerbate symptoms. Elderly patients may be more sensitive to the effects of Detrol and typically require lower dosages.
Contraindications
Detrol is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. It should not be used by patients who have demonstrated hypersensitivity to tolterodine tartrate or any components of the formulation. Patients with known severe hepatic impairment should avoid Detrol unless closely supervised by a healthcare provider with appropriate dosage adjustments. Concurrent use with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin) is contraindicated due to significantly increased tolterodine exposure. The medication is not recommended for use during pregnancy unless clearly needed, and breastfeeding should be discontinued during treatment.
Possible side effect
The most commonly reported side effects include dry mouth (affecting approximately 35% of patients), headache (11%), constipation (7%), and abdominal pain (5%). Other frequently observed adverse reactions include dry eyes, dyspepsia, somnolence, dizziness, and blurred vision. Less common but potentially serious side effects may include urinary retention, angioedema, QT prolongation, and central nervous system effects such as confusion or hallucinations in susceptible individuals. Gastrointestinal side effects typically diminish with continued therapy. Patients should report any persistent or severe side effects to their healthcare provider, particularly difficulty urinating, eye pain (possibly indicating acute narrow-angle glaucoma), or signs of allergic reaction.
Drug interaction
Detrol is primarily metabolized by cytochrome P450 2D6 (CYP2D6) and 3A4 (CYP3A4) enzymes. Concomitant use with potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) is contraindicated. Moderate CYP3A4 inhibitors (erythromycin, fluconazole, verapamil) may increase tolterodine exposure requiring dosage adjustment. Drugs that inhibit CYP2D6 (fluoxetine, paroxetine, quinidine) may increase tolterodine levels in extensive metabolizers. Concurrent use with other anticholinergic agents may potentiate therapeutic and adverse effects. Detrol may reduce the efficacy of medications that stimulate gastrointestinal motility. Caution is advised when combining with drugs that prolong QT interval or cause drowsiness. Pharmacodynamic interactions may occur with other agents affecting bladder function.
Missed dose
If a dose of Detrol is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. For the once-daily extended-release formulation, if missed, take it as soon as remembered unless less than 12 hours remain until the next dose. Consistency in dosing is important for maintaining therapeutic effects, so patients should establish a routine for medication administration. Setting reminders or using pill organizers can help prevent missed doses.
Overdose
In case of suspected overdose, medical attention should be sought immediately. Overdose symptoms may include severe central anticholinergic effects including blurred vision, dilated pupils, dry mouth, difficulty urinating, flushed skin, gastrointestinal disturbances, and CNS effects ranging from drowsiness to agitation. Severe overdose may lead to respiratory depression, cardiac arrhythmias, or convulsions. Treatment is primarily supportive and symptomatic. Activated charcoal may be administered if ingestion was recent. ECG monitoring is recommended due to potential QT prolongation. Physostigmine may be considered for severe central anticholinergic effects in a monitored setting, but should be used with caution due to risk of seizures or bradycardia.
Storage
Detrol should be stored at room temperature (20-25°C or 68-77°F) in the original container, protected from light and moisture. Keep tightly closed when not in use. Do not store in bathrooms or other areas prone to humidity. Keep all medications out of reach of children and pets. Do not use Detrol beyond the expiration date printed on the packaging. Proper disposal of unused medication is important; consult a pharmacist or local waste disposal company for appropriate methods. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Detrol is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and only a healthcare provider can determine the appropriate therapy based on a patient’s specific medical condition, history, and concurrent medications. Patients should not adjust dosage or discontinue treatment without consulting their physician. The complete prescribing information should be reviewed before initiating therapy.
Reviews
Clinical studies involving over 2,000 patients demonstrated that Detrol significantly reduced weekly urge incontinence episodes (median reduction of 71-81% compared to 33-56% for placebo) and decreased urinary frequency. In long-term extension studies, efficacy was maintained for up to 12 months of treatment with consistent safety profile. Patient-reported outcomes showed significant improvements in quality of life measures including social interactions, emotional well-being, and sleep quality. Real-world evidence supports the clinical trial findings, with many patients reporting meaningful improvement in bladder control within the first week of treatment. The extended-release formulation has been particularly praised for its convenience and reduced incidence of dry mouth compared to the immediate-release version.